ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Articles by Natasha Yetman

Regeneron Plans Early Summer Trials for New Antibodies Against Coronavirus

Reuters Staff  |  March 18, 2020

(Reuters)—Regeneron Pharmaceuticals Inc. said on Tuesday it had identified hundreds of antibodies that could treat or prevent the coronavirus (COVID-19) and was preparing to begin clinical trials by early summer, sending the drugmaker’s shares up 12%. The company will select the top two antibodies to develop a “cocktail” treatment and scale up its manufacturing to…

Statins Linked to Reduced Likelihood of Joint Replacement

Reuters Staff  |  March 16, 2020

NEW YORK (Reuters Health)—High-intensity statins are associated with a lower risk of joint replacement, new findings show. “Statins at high intensity may reduce the risk of hip and knee replacement. The effect may be RA specific,” Dr. Aliya Sarmanova of the University of Nottingham, U.K., and colleagues write in Rheumatology.1 Statins have anti-inflammatory effects, and…

Strong Support for Treat-to-Target Strategy in RA Patients

Megan Brooks  |  March 16, 2020

NEW YORK (Reuters Health)—In daily clinical practice, following a treat-to-target (T2T) strategy in patients with rheumatoid arthritis (RA) leads to higher rates of remission compared with not following a T2T strategy, according to a longitudinal analysis of real world data. “The results of the analysis provide direct evidence that following T2T, and particularly sustained T2T,…

Sanofi, Regeneron Begin Testing Arthritis Drug as Coronavirus Treatment

Reuters Staff  |  March 16, 2020

(Reuters)—Sanofi SA and partner Regeneron Pharmaceuticals Inc. have started a clinical trial of their rheumatoid arthritis drug Kevzara (sarilumab) as a treatment for the coronavirus, the companies said on Monday. Enrolments for the mid-to-late stage trial will begin immediately, and the companies anticipate the trial will test up to 400 patients. Sarilumab is an infection-fighting…

Sports Doctors May Accidentally Prescribe Banned Steroids

Lisa Rapaport  |  March 4, 2020

(Reuters Health)—Sports physicians routinely prescribe corticosteroids to athletes for conditions, such as inflammation, asthma and allergies, but not all of them know which forms of these drugs are banned under anti-doping rules, a study suggests. The survey of 603 physicians from 30 countries found four in five prescribe oral corticosteroids to athletes, one of the…

China Approves Use of Tocilizumab for Coronavirus Patients

Reuters Staff  |  March 4, 2020

BEIJING (Reuters)—China will use a Roche Holding AG arthritis drug to treat some coronavirus patients in severe conditions, health authorities said on Wednesday, as the country seeks to build up treatment regimens to help the infected recover. Tocilizumab, sold by the Swiss pharma giant under the trade name Actemra, can be prescribed to coronavirus patients…

Epidemiology of Rheumatoid Arthritis May Be Changing

Will Boggs, MD  |  March 3, 2020

NEW YORK (Reuters Health)’Over the last three decades, there has been a significant decline in the incidence of rheumatoid factor (RF) positive rheumatoid arthritis (RA), while the overall incidence of RA has remained about the same, researchers report. “These trends may suggest changing serological profile of RA over time which may have implications for RA…

Increasing Opioid Dose May Not Help Chronic Pain

David Douglas  |  February 19, 2020

NEW YORK (Reuters Health)—In patients with chronic musculoskeletal pain, an increase in opioid dosage appears to be of no clear benefit, according to a two-year study. As Benjamin J. Morasco, PhD, tells Reuters Health by email, “When we followed patients with chronic pain, who were already prescribed long-term opioid therapy, we found patients as a…

Low-Dose Methotrexate Can Cause Adverse Effects

Will Boggs, MD  |  February 19, 2020

NEW YORK (Reuters Health)—Low-dose methotrexate can be associated with gastrointestinal, pulmonary, infectious, hematologic and other adverse effects, according to an analysis of the Cardiovascular Inflammation Reduction Trial (CIRT). “Methotrexate is not a benign drug, even at dosages used for rheumatic diseases,” Daniel H. Solomon, MD, MPH of Brigham and Women’s Hospital, Boston, tells Reuters Health…

According to MRI, Ultrasound Guidance Does Not Improve Treat-to-Target in RA

Reuters Staff  |  February 5, 2020

NEW YORK (Reuters Health)—Ultrasound guidance does not improve the effectiveness of treat-to-target therapy in rheumatoid arthritis (RA), new findings confirm. “Incorporating ultrasound information in treatment decisions did not lead to reduced MRI inflammation or less structural damage compared with a conventional treatment strategy,” Dr. Ulf Sundin of Diakonhjemmet Hospital, Oslo, and colleagues write in Rheumatology….

  • « Previous Page
  • 1
  • …
  • 17
  • 18
  • 19
  • 20
  • 21
  • …
  • 98
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences